Landos Biopharma (LABP) Stock Analysis

What Landos Biopharma does

Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Another pipeline asset, NX-13, is also an oral therapeutic localized to the gut, targeting the NOD-like receptor X1 (NLRX1) pathway, a mitochondrial receptor involved in regulating inflammatory cytokine production, for UC and CD. Furthermore, LABP-104 is an oral, small-molecule LANCL2 agonist designed to be systemically bioavailable, with potential applications in systemic lupus erythematosus and rheumatoid arthritis (RA). Beyond these clinical programs, Landos maintains a robust preclinical pipeline, featuring several promising compounds: LABP-66, an oral small molecule, acts as a NOD-like pathway agonist and is being explored for multiple sclerosis and Alzheimer's disease. LABP-69 is an oral PLXDC2 agonist targeting diabetic nephropathy and RA. LABP-73, another oral small molecule, modulates the NLRX1 pathway for potential use in asthma and chronic obstructive pulmonary disease. And LABP-111, an oral small molecule LANCL2 pathway agonist, is under investigation for nonalcoholic steatohepatitis and type 1 diabetes. Established in 2017, the company's corporate headquarters are situated in Blacksburg, Virginia.

Key metrics

ETFs linked to LABP

Broad-market and Healthcare sector ETFs an investor holding Landos Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LABP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Landos Biopharma?

Landos Biopharma trades under the ticker LABP on NASDAQ.

Which exchange is LABP listed on?

LABP is listed on NASDAQ.

What sector does Landos Biopharma operate in?

Landos Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LABP in a portfolio?

PortView shows LABP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.